Terms: = Breast cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
5586 results:
1. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in her2-positive and her2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract] [Full Text] [Related]
2. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
3. Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to breast cancer Development.
Pseftogas A; Xanthopoulos K; Siasiaridis A; Poutahidis T; Gonidas C; Tsingotjidou A; Hatzivassiliou E; Mosialos G
Anticancer Res; 2024 May; 44(5):1885-1894. PubMed ID: 38677721
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B breast cancer: A Pilot Study.
Camargo-Herrera V; Castellanos G; Rangel N; Jiménez-Tobón GA; Martínez-Agüero M; Rondón-Lagos M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674062
[TBL] [Abstract] [Full Text] [Related]
5. Impact of Pregnancy on breast cancer Features and prognosis.
Bounous VE; Minella C; Fuso L; Actis S; Petroni G; Sgrò LG; Borghese M; Tomasi Cont N; Ponzone R; Ferrero A
Curr Oncol; 2024 Apr; 31(4):2305-2315. PubMed ID: 38668074
[TBL] [Abstract] [Full Text] [Related]
6. The evolvement of breast cancer therapies: What we have done and where all these head off.
Nurlaila I; Pambudi S
Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
[TBL] [Abstract] [Full Text] [Related]
7. PFDN4 as a Prognostic Marker Was Associated with Chemotherapy Resistance through CREBP1/AURKA Pathway in Triple-Negative breast cancer.
Wang SH; Yeh CH; Wu CW; Hsu CY; Tsai EM; Hung CM; Wang YW; Hsieh TH
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612711
[TBL] [Abstract] [Full Text] [Related]
8. Dual amplification for PEC ultrasensitive aptasensing of biomarker her-2 based on Z-scheme UiO-66/CdIn
Ai QY; Xu BF; Xu F; Wang AJ; Mei LP; Wu L; Song P; Feng JJ
Talanta; 2024 Jul; 274():126034. PubMed ID: 38604040
[TBL] [Abstract] [Full Text] [Related]
9. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/her2-negative BC and TNBC: an exploratory real-world multicentre cohort study.
Peng J; Hong Y; Chen Q; Xu F; Zhang D; Yao J; Zou Q; Yuan L; Li L; Long Q; Liao L; Liu M; Liu X; Wang S; Yi W
Front Endocrinol (Lausanne); 2024; 15():1347762. PubMed ID: 38567311
[TBL] [Abstract] [Full Text] [Related]
11. The prognosis of patients treated with everolimus for advanced ER-positive, her2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract] [Full Text] [Related]
12. The correlation study between TOP2A gene expression in circulating tumor cells and chemotherapeutic drug resistance of patients with breast cancer.
Ye JH; Yu J; Huang MY; Mo YM
Breast Cancer; 2024 May; 31(3):417-425. PubMed ID: 38561479
[TBL] [Abstract] [Full Text] [Related]
13. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
[No Abstract] [Full Text] [Related]
14. Prognostic stratification ability of the CPS+EG scoring system in her2-low and her2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract] [Full Text] [Related]
15. Outcomes of the patients with metastatic male breast cancer.
Dogan I; Khanmammadov N; Ozkurt S; Aydiner A; Saip P
J Cancer Res Ther; 2024 Jan; 20(1):98-102. PubMed ID: 38554305
[TBL] [Abstract] [Full Text] [Related]
16. Potential Value of HSP90α in prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
17. prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010-2020.
Ch'ng ES
Breast Cancer; 2024 May; 31(3):496-506. PubMed ID: 38546966
[TBL] [Abstract] [Full Text] [Related]
18. Protecting the Brain: Novel Strategies for Preventing breast cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models.
Kirchner J; Völker E; Shityakov S; Saji S; Förster CY
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542355
[TBL] [Abstract] [Full Text] [Related]
19. Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
Esmat E; Haidary AM; Saadaat R; Rizvi SN; Aleena S; Haidari M; Hofiani SMS; Hussaini N; Hakimi A; Khairy A; Abdul-Ghafar J
BMC Cancer; 2024 Mar; 24(1):388. PubMed ID: 38539179
[TBL] [Abstract] [Full Text] [Related]
20. DNA Methylation-Regulated HOXC8's Role in her2-Positive breast cancer Function and its Contribution to Herceptin Resistance.
Xie X; Tang S; Yu Z
Discov Med; 2024 Mar; 36(182):559-570. PubMed ID: 38531796
[TBL] [Abstract] [Full Text] [Related]
[Next]
